BeOne Medicines Ltd. has announced a significant agreement to sell its royalty rights on the global sales, excluding China, of Amgen's IMDELLTRA® (tarlatamab-dlle) to Royalty Pharma for up to $950 million. This deal includes an upfront payment of $885 million, with the option for BeOne to sell remaining royalties within the next 12 months for up to an additional $65 million. IMDELLTRA, approved in the U.S. for patients with extensive-stage small cell lung cancer (ES-SCLC) following platinum-based chemotherapy, is a pioneering immunotherapy that targets DLL3-expressing tumor cells. The agreement allows BeOne to retain a portion of the royalty on annual sales exceeding $1.5 billion and continues its collaboration with Amgen for other assets, including the investigational treatment xaluritamig. This move is aimed at enhancing BeOne's financial flexibility and furthering its strategic goals in oncology.